Dolutegravir and raltegravir cause changes to fat cells
Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts
ADVANCE study shows high frequency of major weight gain in women receiving dolutegravir with TAF
Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for cause
Weight gain on HIV treatment: more common with newer drugs, low CD4 counts
Combining statins and physical exercise has big benefits for people with HIV and high lipids
Dolutegravir leads to weight gain in two African studies
The impact of older antiretrovirals on fat redistribution and cardiovascular risk factors may be irreversible
Integrase inhibitor treatment leads to greater weight gain
